Pulmonary Pharmacology · Module 2 of 7

Inhaled Corticosteroids and Combination Controller Therapy

Airway inflammation phenotypes · ICS mechanism and adverse effects · ICS/LABA combinations · SMART therapy · Eosinophil-guided triple therapy

Asthma is a T2-high, eosinophilic disease — IL-4/IL-13/IL-5 from type 2 innate lymphoid cells drive IgE production, goblet cell metaplasia, and eosinophil survival; mast cell degranulation via allergen-IgE crosslinking produces acute bronchoconstriction. This inflammatory cascade is highly glucocorticoid-sensitive: ICS suppress type 2 cytokine transcription, impair eosinophil survival, and stabilize mast cells, producing large consistent reductions in airway inflammation and exacerbation frequency. COPD is T2-low — neutrophilic and macrophage-mediated inflammation driven by smoke/noxious particles, with CD8+ T cells dominant and few eosinophils; this pattern is far less glucocorticoid-sensitive, explaining the smaller ICS effect size in most COPD patients.
ICS act via the glucocorticoid receptor through two mechanisms: transrepression (GR binds NF-κB and AP-1 to block cytokine transcription — responsible for most anti-inflammatory benefit) and transactivation (GR binds glucocorticoid response elements to induce gene expression — responsible for most systemic adverse effects). Lipophilicity governs local retention: fluticasone propionate and furoate are highly lipophilic (membrane depot, prolonged GR occupancy); budesonide forms reversible fatty acid conjugates. High hepatic first-pass extraction (fluticasone ~99%, budesonide ~90%) limits systemic bioavailability from swallowed drug. Ciclesonide and beclomethasone are prodrugs activated by airway esterases, reducing oropharyngeal deposition effects.
ICS adverse effects: local — oral candidiasis (immune suppression at oropharynx; prevented by mouth rinsing + spacer; treated with topical antifungals) and dysphonia (up to 30%; glucocorticoid-induced laryngeal myopathy — rinsing does not prevent; manage by dose reduction or ciclesonide). Systemic (dose-dependent, mainly high doses): HPA axis suppression (risk of secondary adrenal insufficiency on abrupt discontinuation during physiological stress); bone mineral density loss (impaired osteoblast function + increased osteoclast activity + reduced Ca²⁺ absorption; supplement calcium + vitamin D); growth suppression in children (~1.2 cm adult height loss with budesonide in CAMP trial). Fluticasone propionate in COPD: increased pneumonia incidence (TORCH trial) — less with budesonide-containing regimens.
ICS and LABAs exhibit molecular synergy: ICS upregulate beta-2 receptor expression and prevent receptor desensitization; LABAs activate PKA which phosphorylates and activates the GR, enhancing nuclear translocation; both suppress NF-κB and AP-1 through overlapping mechanisms — net effect is equivalent anti-inflammatory control at lower ICS doses. SMART therapy uses budesonide/formoterol as both daily maintenance and as-needed rescue — possible only because formoterol's onset is 1–3 minutes; each rescue dose delivers ICS anti-inflammatory coverage. SYGMA trials: as-needed budesonide/formoterol reduced severe exacerbations versus as-needed SABA alone and was non-inferior to regular maintenance budesonide, at ~25% of the ICS exposure. Salmeterol's slow onset (10–20 min) precludes its use in SMART.
Eosinophil-guided ICS use in COPD: ≥300 cells/µL — consistent exacerbation reduction; triple therapy (ICS/LABA/LAMA) appropriate for recurrent exacerbators. 100–299 cells/µL — intermediate benefit; individualize based on exacerbation burden. <100 cells/µL — little benefit expected; pneumonia risk exceeds benefit; avoid or withdraw ICS. IMPACT trial (n >10,000): single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) reduced exacerbations 25% versus LABA/LAMA and 15% versus ICS/LABA, but with higher confirmed pneumonia rates in fluticasone-containing arms. Step-down in asthma: reduce ICS dose 25–50% after ≥3 months of sustained well-controlled asthma before removing add-on agents.

ACTH = adrenocorticotropic hormone · AP-1 = activator protein-1 · CAMP = Childhood Asthma Management Program · COPD = chronic obstructive pulmonary disease · DPI = dry powder inhaler · FeNO = fractional exhaled nitric oxide · GINA = Global Initiative for Asthma · GOLD = Global Initiative for Chronic Obstructive Lung Disease · GR = glucocorticoid receptor · GRE = glucocorticoid response element · HPA = hypothalamic-pituitary-adrenal · ICS = inhaled corticosteroid · ILC2 = type 2 innate lymphoid cell · LABA = long-acting beta-2 agonist · LAMA = long-acting muscarinic antagonist · MDI = metered-dose inhaler · NF-κB = nuclear factor-kappa B · PKA = protein kinase A · SABA = short-acting beta-2 agonist · SMART = Single Maintenance and Reliever Therapy · TSLP = thymic stromal lymphopoietin

Airway Inflammation Phenotypes

Asthma — T2-High

Eosinophilic Inflammation

Epithelial alarms (IL-25, IL-33, TSLP) activate ILC2s
IL-5 → eosinophil maturation, recruitment, survival
IL-4 / IL-13 → IgE production, goblet cell metaplasia, airway hyperresponsiveness
Allergen-IgE crosslinking → mast cell degranulation → histamine + leukotrienes → acute bronchospasm
Highly glucocorticoid-sensitive — ICS suppress cytokine transcription, impair eosinophil survival, stabilize mast cells

COPD — T2-Low

Neutrophilic Inflammation

Smoke/noxious particles activate macrophages and airway epithelium
IL-8 + LTB4 → neutrophil recruitment
Macrophage proteases (MMP-9, MMP-12) → alveolar wall destruction → emphysema
CD8+ cytotoxic T lymphocytes dominant; few eosinophils in most patients
Glucocorticoid-resistant — ICS benefit limited except when eosinophils ≥300 cells/µL

ICS Mechanism and Agent Profiles

Glucocorticoid Receptor — Two Mechanisms

Transrepression vs. Transactivation

Transrepression: GR binds NF-κB and AP-1 → blocks pro-inflammatory cytokine transcription → most anti-inflammatory benefit
Transactivation: GR binds GRE in gene promoters → induces gene expression → most systemic adverse effects (glucose, bone, HPA)
Developing agents aim to maximize transrepression while minimizing transactivation
ICS + LABA synergy: PKA (from LABA) phosphorylates GR → enhanced nuclear translocation and transcriptional activity

Pharmacokinetic Determinants

Lipophilicity and First-Pass Extraction

Lipophilicity: highly lipophilic agents dissolve into cell membranes → sustained GR occupancy without high free concentrations
Budesonide: forms reversible fatty acid conjugates in airway cells → local retention without extreme lipophilicity
Fluticasone propionate: ~99% first-pass hepatic extraction → very low systemic bioavailability from swallowed drug
Budesonide: ~90% first-pass extraction — both agents systemic-safe despite oropharyngeal deposition
Ciclesonide + beclomethasone: prodrugs activated by airway esterases → reduced oropharyngeal effects

ICS Agent

Fluticasone Propionate / Furoate

Very high GR affinity; highest lipophilicity in class
~99% first-pass extraction (low systemic bioavailability)
Furoate: highest GR affinity available — once-daily dosing
Propionate formulation: increased pneumonia risk in COPD (TORCH trial)

ICS Agent

Budesonide

Intermediate lipophilicity; fatty acid conjugation for airway retention
~90% first-pass extraction
Preferred partner in SMART therapy with formoterol
Lower pneumonia signal than fluticasone propionate in COPD

ICS Agent

Ciclesonide

Prodrug activated by airway esterases to des-ciclesonide (active)
Activation primarily in lower airways → minimal oropharyngeal deposition
Lower rates of oral candidiasis and dysphonia versus other ICS
Option for professional voice users susceptible to dysphonia

ICS Adverse Effects

	Oral Candidiasis	Dysphonia	Systemic (High Dose)
Mechanism	Oropharyngeal drug deposition → local immune suppression → Candida albicans overgrowth	Glucocorticoid-induced myopathy of intrinsic laryngeal muscles — not surface deposition	Systemic absorption → transactivation → HPA suppression, bone loss, glucose changes
Incidence	Common; spacer + rinsing substantially reduce risk	Up to 30% on regular ICS; professional voice users most affected	Clinically significant mainly >1000 mcg/day fluticasone equivalent; children more susceptible
Prevention	Rinse and gargle with water after each dose; spacer use with MDI	Rinsing does NOT prevent; reduce dose, use spacer, or switch to ciclesonide	Lowest effective dose; calcium + vitamin D; monitor bone density at high doses
Treatment	Topical antifungals (clotrimazole, nystatin); fluconazole for persistent cases	Dose reduction; agent switch	Do not abruptly discontinue — risk of secondary adrenal insufficiency during physiological stress

ICS/LABA Combinations and SMART Therapy

ICS/LABA — Twice Daily

Fluticasone / Salmeterol

Available as DPI (Advair Diskus) or pMDI (Advair HFA)
Approved for asthma and COPD maintenance
Salmeterol slow onset (10–20 min) — no rescue use
Pneumonia signal in COPD (propionate component)
SMART not possible with this combination

SMART Therapy

Budesonide / Formoterol

Single inhaler = daily maintenance + as-needed rescue
Formoterol onset 1–3 min — the only LABA suitable for rescue use
Each rescue dose delivers ICS anti-inflammatory coverage
SYGMA trials: fewer severe exacerbations versus SABA alone; ~25% ICS exposure of scheduled therapy
GINA 2024: preferred reliever at all asthma steps

ICS/LABA — Once Daily

Fluticasone Furoate / Vilanterol

Highest GR affinity ICS currently available
Once-daily DPI (Breo Ellipta)
Approved for asthma and COPD
Component of Trelegy Ellipta triple therapy (+ umeclidinium LAMA)
Vilanterol: no rescue use (LABA, slow enough onset)

Eosinophil-Guided ICS Use and Triple Therapy in COPD

Eosinophils ≥300 cells/µL

Add ICS — Clear Benefit

Consistent exacerbation reduction with ICS-containing regimens
Triple therapy (ICS/LABA/LAMA) appropriate for recurrent exacerbators on dual bronchodilators
IMPACT trial: triple therapy reduced exacerbations 25% vs LABA/LAMA

Eosinophils 100–299 cells/µL

Intermediate — Individualize

Intermediate ICS benefit — decision based on exacerbation frequency and severity
Consider ICS addition if two or more moderate or one severe exacerbation per year
Weigh pneumonia risk against exacerbation reduction benefit

Eosinophils <100 cells/µL

Avoid ICS

Little if any exacerbation-reduction benefit expected
Pneumonia risk exceeds benefit — ICS should be withheld or withdrawn
Manage with dual bronchodilator LABA/LAMA therapy

Fluticasone Propionate Pneumonia Signal in COPD

Fluticasone propionate-containing combinations (Advair, Breo with propionate) are associated with increased pneumonia incidence in COPD — established in the TORCH trial and confirmed in subsequent studies. This signal is attenuated or absent with budesonide-containing combinations. When ICS are indicated in COPD, patient-specific pneumonia risk factors — prior pneumonia, low BMI, severe airflow limitation, current smoker — should influence the choice of ICS agent. In high-risk patients, budesonide-containing regimens are preferred over fluticasone propionate.

ICS/LABA Molecular Synergy

ICS and LABAs do not simply co-exist in a fixed-dose inhaler — they enhance each other's pharmacological activity. ICS upregulate beta-2 receptor expression and prevent LABA-induced receptor desensitization by suppressing the kinase responsible for receptor internalization. Conversely, LABA-induced PKA activation phosphorylates the glucocorticoid receptor, enhancing its nuclear translocation and transcriptional efficiency. Both drug classes independently suppress NF-κB and AP-1, producing greater combined cytokine suppression than either drug achieves alone. The clinical consequence is that an ICS/LABA combination achieves equivalent anti-inflammatory control at a lower ICS dose than ICS monotherapy.

Suggested References

Author / Source	Title	Publication
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Barnes PJ	Cellular and molecular mechanisms of asthma and COPD	Clin Sci (Lond). 2017;131(13):1541–1558
Barnes PJ	Inhaled corticosteroids	Pharmaceuticals (Basel). 2010;3(3):514–540
Agusti A, Celli BR, Criner GJ, et al	Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary	Eur Respir J. 2023;61(4):2300239
Lipworth BJ	Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis	Arch Intern Med. 1999;159(9):941–955
Pedersen S	Do inhaled corticosteroids inhibit growth in children?	Am J Respir Crit Care Med. 2001;164(4):521–535
Calverley PM, Anderson JA, Celli B, et al	Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease	N Engl J Med. 2007;356(8):775–789
Singh D, Papi A, Corradi M, et al	Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY)	Lancet. 2016;388(10048):963–973
O'Byrne PM, FitzGerald JM, Bateman ED, et al	Inhaled combined budesonide-formoterol as needed in mild asthma	N Engl J Med. 2018;378(20):1865–1876
Lipson DA, Barnhart F, Brealey N, et al	Once-daily single-inhaler triple versus dual bronchodilator therapy in patients with COPD	N Engl J Med. 2018;378(18):1671–1680
Reddel HK, Bacharier LB, Bateman ED, et al	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes	Am J Respir Crit Care Med. 2022;205(1):17–35
Price D, Musgrave SD, Shepstone L, et al	Leukotriene antagonists as first-line or add-on asthma-controller therapy	N Engl J Med. 2011;364(18):1695–1707
Papi A, Brightling C, Pedersen SE, Reddel HK	Asthma	Lancet. 2018;391(10122):783–800